ClinicalTrials.gg
CompletedNCT03929744Updated Jul 10, 2026Results posted

A Study of LY3502970 in Healthy Participants

A Phase 1 interventional study of LY3502970 and Placebo in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
133
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main purposes of this study are to determine:

  • The safety of LY3502970 and any side effects that might be associated with it.
  • How much LY3502970 gets into the bloodstream and how long it takes the body to get rid of it.

This study has 5 parts (A, B, C, D, and E). Parts A and D involve a single dose of LY3502970 and will last about 15 days. Part B and E involve multiple doses of LY3502970 and will last about 4 weeks. Part C involves two single doses of LY3502970 and will last about 29 days. Each participant will enroll in only one part. Screening must be completed within 28 days before study start. This study is for research purposes only, and is not intended to treat any medical condition.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or females, as determined by medical history
  • Have safety laboratory results within normal reference ranges

Exclusion criteria

Exclusion Criteria:

  • Have known allergies to LY3502970, glucagon-like peptide-1 (GLP-1) analogs, related compounds
  • Abnormal (ECG) at screening
  • Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    Part A 0.3 mg LY3502970

    Participants received a single oral dose of 0.3 milligram (mg) LY3502970.

    Drug: LY3502970

  • Experimental
    Part A 1 mg LY3502970

    Participants received a single oral dose of 1 mg LY3502970.

    Drug: LY3502970

  • Experimental
    Part A 3 mg LY3502970

    Participants received a single oral dose of 3 mg LY3502970.

    Drug: LY3502970

  • Experimental
    Part A 6 mg LY3502970

    Participants received a single oral dose of 6 mg LY3502970.

    Drug: LY3502970

  • Placebo comparator
    Part A Placebo

    Participants received a single oral dose of Placebo.

    Drug: Placebo

  • Placebo comparator
    Part B Placebo

    Participants received oral doses of placebo once daily for 4 weeks.

    Drug: Placebo

  • Experimental
    Part B: 2 mg LY3502970 (Cohort G)

    Participants received oral doses of 2 mg LY3502970 once daily for 4 weeks.

    Drug: LY3502970

  • Experimental
    Part B: 2 / 4 / 6 mg LY3502970 (Cohort H)

    Participants received oral doses of LY3502970 once daily for 4 weeks where 2 mg was given for first week, 4 mg for second week followed by 6 mg on the third and fourth week.

    Drug: LY3502970

  • Experimental
    Part B: 2 / 4 / 8 / 16 mg LY3502970 (Cohort I)

    Participants received oral doses of LY3502970 once daily for 4 weeks where 2 mg was given for first week, 4 mg for second week, 8 mg for third week and 16 mg for fourth week.

    Drug: LY3502970

  • Experimental
    Part B: 2 / 5 / 12 / 24 mg LY3502970 (Cohort J)

    Participants received oral doses of LY3502970 once daily for 4 weeks, where 2 mg was given on first week, 5 mg on second week, 12 mg on third week and 24 mg on fourth week. On day 27, midazolam 200 microgram (mcg) was coadministered with 24 mg LY3502970, and 40 mg atorvastatin administered 4 hours after midazolam.

    Drug: LY3502970 · Drug: Atorvastatin · Drug: Midazolam

  • Experimental
    Part B: 2 / 5 / 12 / 24 mg LY3502970 (Cohort K)

    Participants received oral doses of LY3502970 once daily for 4 weeks, where 2 mg was given on first week, 5 mg on second week, 12 mg on third week and 24 mg on fourth week. On day 27, 20 mg simvastatin was coadministered with 24 mg LY3502970.

    Drug: LY3502970 · Drug: Simvastatin

  • Experimental
    Part C: 3 mg LY3502970 (Fasted/Fed)

    Part C of the study is exploratory, conducted to study exploratory objectives. Participants received a single oral dose of 3 mg LY3502970 in treatment period 1 (fasted condition), followed by administration in treatment period 2 (fed condition), with a washout period of at least 5 days between periods.

    Drug: LY3502970

  • Experimental
    Part C: 3 mg LY3502970 (Fed/Fasted)

    Part C of the study is exploratory, conducted to study exploratory objectives. Participants received a single oral dose of 3 mg LY3502970 in treatment period1 (fed condition), followed by administration in treatment period 2 (fasted condition), with a washout period of at least 5 days between periods.

    Drug: LY3502970

  • Active comparator
    Part D: 3 mg LY3502970 Prototype Formulation

    Part D of the study is exploratory, conducted to study exploratory objectives. Participants received a single oral dose of 3 mg LY3502970 in a controlled-release prototype formulation.

    Drug: LY3502970

  • Placebo comparator
    Part D: Placebo Prototype Formulation

    Part D of the study is exploratory, conducted to study exploratory objectives. Participants received a single oral dose of placebo in a controlled-release prototype formulation.

    Drug: Placebo

  • Experimental
    Part E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 1)

    Part E of the study is exploratory, conducted to study exploratory objectives. Participants received oral doses of LY3502970 once daily for 4 weeks where 2 mg was given for first week, 5 mg for second week, 12 mg for third week and 24 mg as formulation 1 for the fourth week.

    Drug: LY3502970

  • Experimental
    Part E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 2)

    Part E of the study is exploratory, conducted to study exploratory objectives. Participants received oral doses of LY3502970 once daily for 4 weeks where 2 mg was given for first week, 5 mg for second week, 12 mg for third week and 24 mg as formulation 2 for the fourth week.

    Drug: LY3502970

Interventions

06

What researchers measure

Primary outcomes

  1. Parts A and B: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug

    An SAE is any adverse event from this study that results in 1 of the following: Death, initial or prolonged inpatient hospitalization, a life-threatening experience (that is, immediate risk of dying), persistent or significant disability/incapacity, congenital anomaly/birth defect, important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent 1 of the other outcomes listed in the definition above. The number of participants with one or more SAEs considered by the investigator to be related to study drug administration is reported. An overall summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.

    Time frame: Baseline through Follow-up (up to Day 42)

Secondary outcomes

  1. Part A: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970

    PK: Cmax of LY3502970

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96 hours post-dose

  2. Part A: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970

    PK: AUC(0-tlast) of LY3502970

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96 hours post-dose

  3. Part A: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970

    PK: Tmax of LY3502970

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96 hours post-dose

  4. Part B: PK: Maximum Observed Concentration (Cmax) of LY3502970 on Day 1

    PK: Cmax of LY3502970

    Time frame: Day 1 (pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24 hours post-dose)

  5. Part B: PK: Maximum Observed Concentration (Cmax) of LY3502970 on Day 28

    PK: Cmax of LY3502970

    Time frame: Day 28 (pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 96, 168, 336 hours post-dose)

  6. Part B: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 1

    PK: AUC(0-tlast) of LY3502970

    Time frame: Day 1 (pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24 hours post-dose)

  7. Part B: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 28

    PK: AUC(0-tlast) of LY3502970

    Time frame: Day 28 (pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 96, 168, 336 hours post-dose)

  8. Part B: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 on Day 1

    PK: Tmax of LY3502970

    Time frame: Day 1 (pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24 hours post-dose)

  9. Part B: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 on Day 28

    PK: Tmax of LY3502970

    Time frame: Day 28 (pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 96, 168, 336 hours post-dose)

07

Results

Posted Jul 10, 2026

Participant flow

Participant flow — Overall Study
MilestonePart A PlaceboPart A 0.3 mg LY3502970Part A 1 mg LY3502970Part A 3 mg LY3502970Part A 6 mg LY3502970Part B PlaceboPart B: 2 mg LY3502970 (Cohort G)Part B: 2 / 4 / 6 mg LY3502970 (Cohort H)Part B: 2 / 4 / 8 / 16 mg LY3502970 (Cohort I)Part B: 2 / 5 / 12 / 24 mg LY3502970 (Cohort J)Part B: 2 / 5 / 12 / 24 mg LY3502970 (Cohort K)Part C: 3 mg LY3502970 (Fasted/Fed)Part C: 3 mg LY3502970 (Fed/Fasted)Part D: 3 mg LY3502970 Prototype FormulationPart D: Placebo Prototype FormulationPart E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 1)Part E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 2)
Started86666159999966621110
Received at least one dose of study drug86666159999966621110
Completed8664613887986652910
Not completed00020211201001020
Withdrew: Lost to follow-up00020101100000000
Withdrew: Adverse event00000100001000010
Withdrew: Withdrawal by subject00000010100001000
Withdrew: Physician decision00000000000000010

Outcome measures

PrimaryParts A and B: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug

An SAE is any adverse event from this study that results in 1 of the following: Death, initial or prolonged inpatient hospitalization, a life-threatening experience (that is, immediate risk of dying), persistent or significant disability/incapacity, congenital anomaly/birth defect, important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent 1 of the other outcomes listed in the definition above. The number of participants with one or more SAEs considered by the investigator to be related to study drug administration is reported. An overall summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.

Time frame:
Baseline through Follow-up (up to Day 42)
Reported as:
Count of participants · Participants
Parts A and B: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug
ParticipantsPart A PlaceboPart A 0.3 mg LY3502970Part A 1 mg LY3502970Part A 3 mg LY3502970Part A 6 mg LY3502970Part B PlaceboPart B: 2 mg LY3502970Part B: 4 mg LY3502970Part B: 5 mg LY3502970Part B: 6 mg LY3502970Part B: 8 mg LY3502970Part B: 12 mg LY3502970Part B: 16 mg LY3502970Part B: 24 mg LY3502970
Parts A and B: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug00000000000000
SecondaryPart A: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970

PK: Cmax of LY3502970

Time frame:
Pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96 hours post-dose
Reported as:
Geometric mean · Nanograms per milliliter (ng/mL)
Part A: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970
Nanograms per milliliter (ng/mL)Part A 0.3 mg LY3502970Part A 1 mg LY3502970Part A 3 mg LY3502970Part A 6 mg LY3502970
Part A: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY35029701.45 ± 484.02 ± 3614.9 ± 2012.9 ± 43
SecondaryPart A: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970

PK: AUC(0-tlast) of LY3502970

Time frame:
Pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96 hours post-dose
Reported as:
Geometric mean · nanograms*hours per milliliter (ng*h/mL)
Part A: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970
nanograms*hours per milliliter (ng*h/mL)Part A 0.3 mg LY3502970Part A 1 mg LY3502970Part A 3 mg LY3502970Part A 6 mg LY3502970
Part A: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY350297034.0 ± 4189.1 ± 54362 ± 28440 ± 8
SecondaryPart A: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970

PK: Tmax of LY3502970

Time frame:
Pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96 hours post-dose
Reported as:
Geometric mean · hours
Part A: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970
hoursPart A 0.3 mg LY3502970Part A 1 mg LY3502970Part A 3 mg LY3502970Part A 6 mg LY3502970
Part A: PK: Time of Maximum Observed Concentration (Tmax) of LY35029708 (4.05 to 16.15)4.05 (4.05 to 8)6.04 (4.05 to 8)12.04 (8.07 to 16.02)
SecondaryPart B: PK: Maximum Observed Concentration (Cmax) of LY3502970 on Day 1

PK: Cmax of LY3502970

Time frame:
Day 1 (pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24 hours post-dose)
Reported as:
Geometric mean · ng/mL
Part B: PK: Maximum Observed Concentration (Cmax) of LY3502970 on Day 1
ng/mLPart B: 2 mg LY3502970 (Cohorts G-K).
Part B: PK: Maximum Observed Concentration (Cmax) of LY3502970 on Day 18.40 ± 33
SecondaryPart B: PK: Maximum Observed Concentration (Cmax) of LY3502970 on Day 28

PK: Cmax of LY3502970

Time frame:
Day 28 (pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 96, 168, 336 hours post-dose)
Reported as:
Geometric mean · ng/mL
Part B: PK: Maximum Observed Concentration (Cmax) of LY3502970 on Day 28
ng/mLPart B: 2 mg LY3502970 (Cohort G)Part B: 6 mg LY3502970 (Cohort H)Part B: 16 mg LY3502970 (Cohort I)Part B: 24 mg LY3502970 (Cohorts J, K)
Part B: PK: Maximum Observed Concentration (Cmax) of LY3502970 on Day 2811.1 ± 3634.4 ± 2368.2 ± 5199.6 ± 92
SecondaryPart B: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 1

PK: AUC(0-tlast) of LY3502970

Time frame:
Day 1 (pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24 hours post-dose)
Reported as:
Geometric mean · ng*h/mL
Part B: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 1
ng*h/mLPart B: 2 mg LY3502970 (Cohorts G-K).
Part B: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 1118 ± 29
SecondaryPart B: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 28

PK: AUC(0-tlast) of LY3502970

Time frame:
Day 28 (pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 96, 168, 336 hours post-dose)
Reported as:
Geometric mean · ng*h/mL
Part B: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 28
ng*h/mLPart B: 2 mg LY3502970 (Cohort G)Part B: 6 mg LY3502970 (Cohort H)Part B: 16 mg LY3502970 (Cohort I)Part B: 24 mg LY3502970 (Cohorts J, K)
Part B: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 28428 ± 431300 ± 683080 ± 603490 ± 90
SecondaryPart B: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 on Day 1

PK: Tmax of LY3502970

Time frame:
Day 1 (pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24 hours post-dose)
Reported as:
Median · hours
Part B: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 on Day 1
hoursPart B: 2 mg LY3502970 (Cohorts G-K).
Part B: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 on Day 18 (3.92 to 12.02)
SecondaryPart B: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 on Day 28

PK: Tmax of LY3502970

Time frame:
Day 28 (pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, 96, 168, 336 hours post-dose)
Reported as:
Median · hours
Part B: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 on Day 28
hoursPart B: 2 mg LY3502970 (Cohort G)Part B: 6 mg LY3502970 (Cohort H)Part B: 16 mg LY3502970 (Cohort I)Part B: 24 mg LY3502970 (Cohorts J, K)
Part B: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 on Day 284.08 (2.00 to 8.00)8.00 (4.07 to 12.17)6.06 (2.00 to 12.13)8.08 (0.00 to 24.00)

Adverse events

Collected over Baseline through Follow-up (up to Day 42). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A Placebo0/8 (0%)0/8 (0%)1/8 (12.5%)
Part A 0.3 mg LY35029700/6 (0%)0/6 (0%)1/6 (16.7%)
Part A 1 mg LY35029700/6 (0%)0/6 (0%)1/6 (16.7%)
Part A 3 mg LY35029700/6 (0%)0/6 (0%)3/6 (50%)
Part A 6 mg LY35029700/6 (0%)0/6 (0%)5/6 (83.3%)
Part B Placebo QD0/15 (0%)0/15 (0%)4/15 (26.7%)
Part B 2 mg LY3502970 QD0/45 (0%)0/45 (0%)16/45 (35.6%)
Part B 4 mg LY3502970 QD0/18 (0%)0/18 (0%)8/18 (44.4%)
Part B 5 mg LY3502970 QD0/17 (0%)0/17 (0%)6/17 (35.3%)
Part B 6 mg LY3502970 QD0/8 (0%)0/8 (0%)5/8 (62.5%)
Part B 8 mg LY3502970 QD0/9 (0%)0/9 (0%)6/9 (66.7%)
Part B 12 mg LY3502970 QD0/17 (0%)0/17 (0%)8/17 (47.1%)
Part B 16 mg LY3502970 QD0/8 (0%)0/8 (0%)2/8 (25%)
Part B 24 mg LY3502970 QD0/17 (0%)0/17 (0%)9/17 (52.9%)
Part C 3 mg LY3502970 Fasted0/12 (0%)0/12 (0%)2/12 (16.7%)
Part C 3 mg LY3502970 Fed0/12 (0%)0/12 (0%)0/12 (0%)
Part D: 3 mg LY3502970 Prototype Formulation0/6 (0%)0/6 (0%)2/6 (33.3%)
Part D: Placebo Prototype Formulation0/2 (0%)0/2 (0%)0/2 (0%)
Part E 2 mg LY3502970 QD0/21 (0%)0/21 (0%)4/21 (19%)
Part E 5 mg LY3502970 QD0/20 (0%)0/20 (0%)4/20 (20%)
Part E 12 mg LY3502970 QD0/19 (0%)0/19 (0%)6/19 (31.6%)
Part E 24 mg LY3502970 QD0/19 (0%)0/19 (0%)5/19 (26.3%)
Part E 24 mg LY3502970 Formulation 1 QD0/9 (0%)0/9 (0%)0/9 (0%)
Part E 24 mg LY3502970 Formulation 2 QD0/10 (0%)0/10 (0%)1/10 (10%)
Most frequent other events
Showing 10 of 38
Most frequent other events
EventPart A PlaceboPart A 0.3 mg LY3502970Part A 1 mg LY3502970Part A 3 mg LY3502970Part A 6 mg LY3502970Part B Placebo QDPart B 2 mg LY3502970 QDPart B 4 mg LY3502970 QDPart B 5 mg LY3502970 QDPart B 6 mg LY3502970 QDPart B 8 mg LY3502970 QDPart B 12 mg LY3502970 QDPart B 16 mg LY3502970 QDPart B 24 mg LY3502970 QDPart C 3 mg LY3502970 FastedPart C 3 mg LY3502970 FedPart D: 3 mg LY3502970 Prototype FormulationPart D: Placebo Prototype FormulationPart E 2 mg LY3502970 QDPart E 5 mg LY3502970 QDPart E 12 mg LY3502970 QDPart E 24 mg LY3502970 QDPart E 24 mg LY3502970 Formulation 1 QDPart E 24 mg LY3502970 Formulation 2 QD
VomitingGastrointestinal disorders0/80/60/63/64/60/152/450/180/170/81/91/170/83/171/120/120/60/23/210/203/191/190/91/10
NauseaGastrointestinal disorders0/80/60/63/63/60/155/454/181/174/83/93/171/82/172/120/121/60/22/211/204/193/190/91/10
HeadacheNervous system disorders0/80/61/60/62/60/153/454/181/173/80/94/170/85/171/120/121/60/21/211/202/191/190/90/10
ConstipationGastrointestinal disorders0/80/60/60/60/60/155/456/183/171/82/92/170/82/170/120/121/60/20/211/200/190/190/90/10
Abdominal distensionGastrointestinal disorders0/80/60/60/60/60/151/450/180/170/80/91/170/81/170/120/121/60/21/210/200/191/190/90/10
Abdominal painGastrointestinal disorders0/80/60/60/61/60/156/451/180/171/80/90/170/81/170/120/120/60/21/210/200/190/190/90/10
Abdominal pain lowerGastrointestinal disorders0/80/60/60/60/60/150/450/180/170/80/90/170/80/170/120/121/60/20/210/200/190/190/90/10
HaematocheziaGastrointestinal disorders0/80/60/60/61/60/150/450/180/170/80/90/170/80/170/120/120/60/20/210/200/190/190/90/10
Electrocardiogram t wave inversionInvestigations0/80/60/60/61/60/150/450/180/170/80/90/170/80/170/120/120/60/20/210/200/190/190/90/10
Decreased appetiteMetabolism and nutrition disorders0/80/60/60/61/60/154/451/181/171/81/90/170/80/170/120/120/60/22/210/202/190/190/90/10

Baseline characteristics

All enrolled participants.

Age, Categorical
Age, Categorical(Participants)Part A PlaceboPart A 0.3 mg LY3502970Part A 1 mg LY3502970Part A 3 mg LY3502970Part A 6 mg LY3502970Part B PlaceboPart B: 2 mg LY3502970 (Cohort G)Part B: 2 / 4 / 6 mg LY3502970 (Cohort H)Part B: 2 / 4 / 8 / 16 mg LY3502970 (Cohort I)Part B: 2 / 5/ 12 / 24 mg LY3502970 (Cohort J)Part B: 2 / 5/ 12 / 24 mg LY3502970 (Cohort K)Part C: 3 mg LY3502970 (Fasted/Fed)Part C: 3 mg LY3502970 (Fed/Fasted)Part D: 3 mg LY3502970 Prototype FormulationPart D: Placebo Prototype FormulationPart E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 1)Part E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 2)Total
<=18 years000000000000000000
Between 18 and 65 years86666159999966621110133
>=65 years000000000000000000
Sex: Female, Male
Sex: Female, Male(Participants)Part A PlaceboPart A 0.3 mg LY3502970Part A 1 mg LY3502970Part A 3 mg LY3502970Part A 6 mg LY3502970Part B PlaceboPart B: 2 mg LY3502970 (Cohort G)Part B: 2 / 4 / 6 mg LY3502970 (Cohort H)Part B: 2 / 4 / 8 / 16 mg LY3502970 (Cohort I)Part B: 2 / 5/ 12 / 24 mg LY3502970 (Cohort J)Part B: 2 / 5/ 12 / 24 mg LY3502970 (Cohort K)Part C: 3 mg LY3502970 (Fasted/Fed)Part C: 3 mg LY3502970 (Fed/Fasted)Part D: 3 mg LY3502970 Prototype FormulationPart D: Placebo Prototype FormulationPart E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 1)Part E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 2)Total
Female2331433240413211138
Male633521267595534110995
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A PlaceboPart A 0.3 mg LY3502970Part A 1 mg LY3502970Part A 3 mg LY3502970Part A 6 mg LY3502970Part B PlaceboPart B: 2 mg LY3502970 (Cohort G)Part B: 2 / 4 / 6 mg LY3502970 (Cohort H)Part B: 2 / 4 / 8 / 16 mg LY3502970 (Cohort I)Part B: 2 / 5/ 12 / 24 mg LY3502970 (Cohort J)Part B: 2 / 5/ 12 / 24 mg LY3502970 (Cohort K)Part C: 3 mg LY3502970 (Fasted/Fed)Part C: 3 mg LY3502970 (Fed/Fasted)Part D: 3 mg LY3502970 Prototype FormulationPart D: Placebo Prototype FormulationPart E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 1)Part E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 2)Total
Hispanic or Latino5111252522522113141
Not Hispanic or Latino35554107477444518992
Unknown or Not Reported000000000000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A PlaceboPart A 0.3 mg LY3502970Part A 1 mg LY3502970Part A 3 mg LY3502970Part A 6 mg LY3502970Part B PlaceboPart B: 2 mg LY3502970 (Cohort G)Part B: 2 / 4 / 6 mg LY3502970 (Cohort H)Part B: 2 / 4 / 8 / 16 mg LY3502970 (Cohort I)Part B: 2 / 5/ 12 / 24 mg LY3502970 (Cohort J)Part B: 2 / 5/ 12 / 24 mg LY3502970 (Cohort K)Part C: 3 mg LY3502970 (Fasted/Fed)Part C: 3 mg LY3502970 (Fed/Fasted)Part D: 3 mg LY3502970 Prototype FormulationPart D: Placebo Prototype FormulationPart E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 1)Part E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 2)Total
American Indian or Alaska Native000000000000000000
Asian010000100001000014
Native Hawaiian or Other Pacific Islander000000000000000000
Black or African American1230084324303406548
White7336674673653224478
More than one race000000000200000103
Unknown or Not Reported000000000000000000
Region of Enrollment
Region of Enrollment(Participants)Part A PlaceboPart A 0.3 mg LY3502970Part A 1 mg LY3502970Part A 3 mg LY3502970Part A 6 mg LY3502970Part B PlaceboPart B: 2 mg LY3502970 (Cohort G)Part B: 2 / 4 / 6 mg LY3502970 (Cohort H)Part B: 2 / 4 / 8 / 16 mg LY3502970 (Cohort I)Part B: 2 / 5/ 12 / 24 mg LY3502970 (Cohort J)Part B: 2 / 5/ 12 / 24 mg LY3502970 (Cohort K)Part C: 3 mg LY3502970 (Fasted/Fed)Part C: 3 mg LY3502970 (Fed/Fasted)Part D: 3 mg LY3502970 Prototype FormulationPart D: Placebo Prototype FormulationPart E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 1)Part E: 2 / 5 / 12 / 24 mg LY3502970 (24 mg as Formulation 2)Total
United States86666159999966621110133
08

Study locations

1 site
  • Covance Dallas
    Dallas, Texas 75247, United States
09

References and documents

Publications

  • Ma X, Liu R, Pratt EJ, Benson CT, Bhattachar SN, Sloop KW. Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Ther. 2024 Apr;15(4):819-832. doi: 10.1007/s13300-024-01554-1. Epub 2024 Feb 24. PubMed 38402332 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Nov 2020, 16 months.

Results were first posted in Jul 2026, 5 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2019
First posted
Apr 29, 2019
StartActual
Jun 12, 2019
Primary completionActual
Nov 2, 2020
CompletionActual
Nov 2, 2020
Results first posted
Jul 10, 2026
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03929744
Responsible party
Sponsor
First posted
Apr 29, 2019
Start date
Jun 12, 2019
Primary completion
Nov 2, 2020
Completion
Nov 2, 2020
Results posted
Jul 10, 2026
Last update
Jul 10, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion